SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals (CRML) is trending following news of a potential U.S. government stake in the company to secure rare earth mineral supply chains. Community members are discussing the implications of this government interest, comparing it to similar situations with other companies, and anticipating a significant rise in share price. The focus remains on CRML's access to the Greenland rare earth mine and its potential to become a key player in the U.S. critical minerals sector.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is trending as the community rallies around its strong IRL presence and continues building its ecosystem.  Enthusiastic community members are highlighting the increasing holder count and the numerous real-world products associated with the brand, creating a strong sense of long-term potential. The community's focus remains on building the brand and expanding its reach, signaling confidence in Kendu's future.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending amid community excitement, with potential CoinMarketCap (CMC) listing buzz circulating. The community highlights the token's strong holders and uplifting narrative, emphasizing its position within the Solana and PUMP ecosystems. Discussions also focus on WAGMI's potential for long-term growth.

Gremly

Gremly Crypto is trending as the community draws comparisons to other meme coins like Pepe and Shiba Inu, with some highlighting the potential for significant gains. Conversations revolve around its chart patterns and community promotion efforts, as well as mentions of the contract address. The crypto is also being discussed alongside other trending tokens like UpDog.

Linea is the Layer 2 built from first principles to strengthen Ethereum and the entire ETH economy. Every aspect of its design—from its productive ETH burn mechanics, and capital efficient native yield, to its underlying Ethereum-equivalent zk tech—amplifies the value and utility of Ethereum Mainnet. All of this is backed by the largest ecosystem fund in the space, managed by the most trusted Ethereum builders. With institutional-grade infrastructure, and deep integration across DeFi, Linea is the best chain for ETH capital, where every transaction and every block strengthens Ethereum. Linea is where Ethereum wins.

Linea

Linea is trending as the community discusses its potential integration with the SWIFT network, with some suggesting it could impact other cryptocurrencies like XRP. Community members are also sharing positive opinions on Linea's underlying technology and its potential for future growth within the Ethereum ecosystem. Some users are also pointing to potential token dilution as a possible headwind.

Themes ETF Trust - Themes Humanoid Robotics ETF

Themes ETF Trust - Themes Robotics & Automation ETF

BOTT is trending amid discussions about robotics and automation ETFs and their potential exposure to the growing humanoid robotics sector. Community members are comparing different ETFs and evaluating their holdings in light of potential IPOs of robotics companies. Some investors are highlighting the long-term growth potential of robotics and AI, while others are noting trading halts for the stock.

eCash (XEC) is a Layer-1 digital cash network, developed by Bitcoin ABC. It was created on Nov 15th, 2020, and has since distinguished itself from its predecessors and other Bitcoin clients by integrating the breakthrough Avalanche consensus with its core proof-of-work (PoW) layer, extending its security and fundamental capabilities.  This hybrid consensus integration gives it unique properties for a Bitcoin-like chain, such as interoperability, staking rewards, real-time processing, and an improved overall extensibility, which is hard to achieve in a completely trustless manner using only Nakamoto consensus.  The development roadmap is set with three main goals: Scaling transaction throughput from ~100 tps to more than 5.000.000 tps Improving the payment experience with a less than 3 second transaction finality time Extending the protocol and establishing fork-free upgrade routines, allowing for more rapid, iterative development

eCash

eCash is trending as the Electronic Cash Conference 2025 approaches, with the community buzzing about the upcoming keynotes and presentations focused on network efficiency, scalability, and Bitcoin script applications. Recent developments like NOWNodes adding eCash transaction tracking and new listings on Houdini Swap are also generating interest. The community is also excited about the local eCash v1.5.0 release, staking rewards, and the recent Bitcoin ABC maintenance release.

Proof Of Liquidity

Polygon's POL is trending as the community discusses its zkEVM scaling narrative and the launch of Katana's private mainnet, including a $KAT token airdrop for POL stakers. Positive sentiment is building around partnerships with major players like Adobe and Flipkart, which are seen as institutional validation. Traders are also closely watching its performance relative to BTC and ETH, with some anticipating a significant rally.

ARK Investment Management LLC - ARK Autonomous Technology & Robotics ETF

ARK Autonomous Technology & Robotics ETF

ARKQ is trending as the ETF's exposure to autonomous technology and robotics, particularly companies involved in space exploration like $LUNR, attracts attention. Community members are comparing ARKQ's potential to that of $PLTR, citing government and private sector growth opportunities. Discussions also highlight ARKQ's strong performance relative to the QQQ and other ARKK funds, with some emphasizing that it has matched QQQ's 5-year return.

KraneShares Trust - KraneShares Global Humanoid and Embodied Intelligence Index ETF

KraneShares Global Humanoid and Embodied Intelligence Index ETF

KOID is trending as discussions center on the potential of humanoid robotics and AI, especially in China, where government initiatives and investments are driving sector growth. Community members are comparing KOID to other robotics ETFs like $HUMN and $ARKQ, while highlighting Unitree Robotics' planned IPO and its potential impact on related ETFs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Omeros Corporation has filed a marketing authorization application (MAA) with the European Medicines Agency (EMA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).The MAA is based on response-evaluable analyses of patients treated with narsoplimab and a comparison of overall survival with a well-matched external control group.&nbsp;According to the company, the submission shows a 61% response rate and a three-fold improvement in overall survival in the narsoplimab cohort.&nbsp;It also incorporates outcomes from over 130 patients treated under Omeros’ expanded access program.Following the news, H.C. Wainwright reiterated a ‘Buy’ rating and $9 price target on the stock.&nbsp;Analyst Brandon Folkes wrote that the EMA submission supports the view that Omeros “may be entering a phase of rerating” over the next 12 months, driven by potential U.S. approval, EU approval, and renewed appreciation for the broader pipeline.&nbsp;The firm expects narsoplimab to secure regulatory clearance in both regions, creating “significant value” for the company.On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.Retail investors voiced concerns after Omeros Corporation’s June 27 shareholder meeting, during which audio reportedly cut out during two critical questions on the company's regulatory outlook.One user claimed that approximately 80 seconds of the meeting, covering responses to questions about the status of the biologics license application (BLA) and the FDA’s ability to meet its PDUFA timeline, were missing from both the live broadcast and its replay.&nbsp;<stembedurl>https://stocktwits.com/WinstonWolfff/message/619393411</stembedurl>“We, as shareholders, deserve to hear the complete responses,” they wrote, adding that Omeros has “a HUGE shareholder relations/communication problem.”Another investor said they emailed Omeros directly, describing the audio loss during the “most important two questions regarding FDA approval” as “beyond embarrassing.”&nbsp;<stembedurl>https://stocktwits.com/TRYII/message/619392905</stembedurl>The user called for a full update and transcript, writing: “Please do the right thing here… Many, many investors are asking and suspicious.”<a href="https://stocktwits.com/symbol/OMER">Omeros'</a> stock has declined 67.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Omeros Seeks EMA Approval For Narsoplimab After Data Shows 3X Survival Boost

The application includes outcomes from more than 130 patients treated under an expanded access program, supporting broader regulatory momentum for narsoplimab. 

Equity

Down 54.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Omeros (OMER)

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Omeros Corporation (Nasdaq: OMER) today announced statistical analysis results related to the expanded access program (EAP) for narsoplimab, Omeros first-in-class monoclonal antibody inhibiting the...

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Omeros Corporation (Nasdaq: OMER) today announced the availability on its website of materials accompanying two presentations given at the 2025 Tandem Meetings the Transplantation & Cellular Therapy...

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings the Transplantation & Cellular Therapy Meetings of the American Society for...

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

Omeros Corporation (Nasdaq: OMER) today announced statistical sensitivity analysis results related to the primary endpoint analysis for narsoplimab, Omeros first-in-class monoclonal antibody...

Omeros Narsoplimab Meets its Pivotal Trial Primary Endpoint Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Omeros Corporation (Nasdaq: OMER) today announced that an independent statistical group has completed the primary statistical analysis agreed with the FDA for narsoplimab, Omeros first-in-class...

Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting

Omeros Corporation (Nasdaq: OMER) today announced that two posters directed to zaltenibart (OMS906), Omeros investigational inhibitor of MASP-3, the key and most proximal activator of the alternative...

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Omeros Corporation (Nasdaq: OMER) today announced that two abstracts directed to zaltenibart (OMS906), Omeros investigational inhibitor of MASP-3, the key activator of the alternative pathway of...

Omeros Corporation Provides Update on Progress Toward BLA Resubmission

Omeros Corporation (Nasdaq: OMER) today announced an update on its progress toward planned resubmission of its biologics license application (BLA) for narsoplimab, the companys first-in-class...

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.45	--	--	N/A
Q2 '25	-$0.50	-$0.43	14.47%	BEAT
Q1 '25	-$0.57	-$0.58	-2.50%	MISSED
Q4 '24	-$0.78	-$0.54	30.37%	BEAT
Q3 '24	-$0.70	-$0.56	20.57%	BEAT

OMER
Omeros Corporation

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest OMER News

OMER Omeros Corporation